Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Abnormal bleeding tendency (abnormal bleeding), Ecchymosis, Abnormal umbilical stump bleeding, and Factor XIII subunit A deficiency and others; and common findings: Spontaneous hematomas and Persistent bleeding after trauma. 12 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 4 | Abnormal bleeding tendency (abnormal bleeding), Abnormal umbilical stump bleeding, Persistent bleeding after trauma |
F13A1 encodes coagulation factor XIII A chain (732 aa). Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Highest expression in Adipose Visceral Omentum (110.3 TPM) and Adipose Subcutaneous (106.0 TPM).
Factor XIII, A subunit, deficiency of is caused by mutations in the F13A1 gene on chromosome 6.
F13A1 is classified as a druggable target (Druggable Genome and Enzyme categories) with score 17.4.
Genetic testing for F13A1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 7 always present features, 2 common features.
No clinical trials have been registered for factor XIII, A subunit, deficiency of.
7 publications have been identified in PubMed for factor XIII, A subunit, deficiency of. Research spans Case Report / Case Series (43%), Basic Science / Preclinical (43%), and Review / Meta-Analysis (14%).
Pieples LA (2026). [PMID: 42184124](https://pubmed.ncbi.nlm.nih.gov/42184124/). *J Vet Intern Med*. [Case Report / Case Series]
Jacobs JW (2026). [PMID: 41583548](https://pubmed.ncbi.nlm.nih.gov/41583548/). *Clin Hematol Int*. [Review / Meta-Analysis]
Wang M (2026). [PMID: 41524096](https://pubmed.ncbi.nlm.nih.gov/41524096/). *Mol Genet Genomic Med*. [Case Report / Case Series]
Odame J (2025). [PMID: 40893649](https://pubmed.ncbi.nlm.nih.gov/40893649/). *Res Pract Thromb Haemost*. [Case Report / Case Series]
Del Carpio-Cano F (2025). [PMID: 39995753](https://pubmed.ncbi.nlm.nih.gov/39995753/). *Res Pract Thromb Haemost*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 11:54 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Bones and joints | 1 | Joint hemorrhage |
Heart and blood vessels | 1 | Intracranial hemorrhage |
Del Carpio-Cano F (2024). [PMID: 39763522](https://pubmed.ncbi.nlm.nih.gov/39763522/). *medRxiv*. [Basic Science / Preclinical]
AI-curated news mentioning factor XIII, A subunit, deficiency of
Updated Mar 2, 2026
A recent publication discusses the current management and care gaps for Factor II and Factor V deficiencies, highlighting the need for therapeutic advancements. The article calls for increased research and innovation to improve patient outcomes in these rare bleeding disorders.